ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly non-major products combined — U.S. revenue ($M) [Q1–Q3 10-Q & FY 10-K] ($M)
Form 10-Q / 10-K MD&A
Latest, Q2 2026
1,842
Period ended Jun 30, 2026
Change on a year earlier
-42.5%
3,204 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
34
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Eli Lilly Non-major products combined — U.S. revenue ($M) [Q1–Q3 10-Q & FY 10-K] ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_other_products_us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.